

Primary Ciliary Dyskinesia Market Size, Share and Growth Outlook 2026: By Treatment (Pharmacological Therapy, Gene Therapy, Supportive Care), By Diagnostic Tool, By Disease Manifestation, By Patient Age Group, Companies to 2034.

<https://marketpublishers.com/r/P6E60F63108AEN.html>

Date: July 2026

Pages: 190

Price: US\$ 3,482.00 (Single User License)

ID: P6E60F63108AEN

Abstracts

The global Primary Ciliary Dyskinesia Market size is forecast to increase from \$572.5 Million in 2026 to \$902.88 Million in 2034 at a CAGR of 5.86% between 2026 and 2034.

The Primary Ciliary Dyskinesia market report provides detailed analysis and outlook of Primary Ciliary Dyskinesia segments including By Treatment (Pharmacological Therapy, Gene Therapy, Supportive Care), By Diagnostic Tool (Genetic Testing, Nasal Nitric Oxide Measurement, High-Speed Video Microscopy), By Disease Manifestation (Pulmonary Disease, Situs Abnormality, Infertility, Eye disorders), By Patient Age Group (0-5 Years, 6-20 Years, 21-40 Years, 40+ Years) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Primary Ciliary Dyskinesia Industry Overview

Genetic Medicine Innovations are Transforming the Therapeutic Landscape for Primary Ciliary Dyskinesia

The Primary Ciliary Dyskinesia (PCD) industry is entering a transformative phase driven by advances in genetic medicine, precision diagnostics, and disease-modifying therapeutic development. Historically managed through supportive respiratory care and symptom control strategies, Primary Ciliary Dyskinesia is increasingly becoming a target for molecular therapies designed to address the underlying genetic defects responsible

for impaired ciliary function. The growing understanding of genotype-specific disease mechanisms, coupled with advancements in messenger RNA therapeutics, gene delivery technologies, and respiratory drug administration systems, is accelerating clinical development activity across the rare respiratory disease landscape. Simultaneously, international research networks and clinical collaborations are establishing standardized diagnostic and efficacy assessment frameworks to support the advancement of novel therapeutic approaches.

Messenger RNA Therapeutics are Emerging as a Promising Disease-Modifying Strategy

The development of targeted genetic therapies represents one of the most significant advancements in the treatment of Primary Ciliary Dyskinesia. Researchers and biotechnology companies are increasingly leveraging messenger RNA technologies to restore defective protein expression and normalize ciliary function within affected respiratory tissues. ReCode Therapeutics has demonstrated the clinical potential of this approach through its inhaled mRNA therapeutic candidate targeting DNAI1-associated Primary Ciliary Dyskinesia. Utilizing its proprietary Selective Organ Targeting lipid nanoparticle platform, the therapy delivers functional DNAI1 messenger RNA directly to respiratory tissues. Clinical findings demonstrated meaningful improvements in mucociliary clearance among a majority of treated patients, while bronchoscopic evaluations confirmed successful restoration of dynein arm protein expression and functional ciliary movement. These outcomes represent a significant milestone in the development of disease-modifying therapies capable of addressing the underlying pathophysiology of Primary Ciliary Dyskinesia.

International Clinical Networks are Establishing Standardized Frameworks for Therapeutic Development

The advancement of orphan respiratory therapies increasingly depends on coordinated international clinical research infrastructures capable of supporting multicenter studies and standardized outcome measurements. The Primary Ciliary Dyskinesia Clinical Trial Network and ERN-LUNG have strengthened this framework through comprehensive evaluations of specialized investigator sites and longitudinal patient cohorts, establishing mucociliary clearance as a standardized primary clinical endpoint for future disease-modifying therapies. These efforts address a critical need for reproducible efficacy measurements across genetically diverse patient populations. In parallel, the BEAT-PCD Clinical Research Collaboration has expanded its global activities through extended international research initiatives focused on harmonizing diagnostic

algorithms, updating genetic classification frameworks, and standardizing therapeutic management practices across participating institutions. Such collaborative efforts are creating the clinical infrastructure necessary to accelerate the development, evaluation, and commercialization of emerging therapies for this rare genetic respiratory disorder.

Primary Ciliary Dyskinesia Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Primary Ciliary Dyskinesia market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Parion Sciences, ReCode Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Reata Pharmaceuticals, Ethris GmbH, Vertex Pharmaceuticals, Nobelpharma Co., Ltd., Bayer AG, GlaxoSmithKline plc. The Primary Ciliary Dyskinesia market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Primary Ciliary Dyskinesia industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.

The report provides detailed market analysis including-

- Growth Primary Ciliary Dyskinesia Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Primary Ciliary Dyskinesia companies

- Porter's Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

- Detailed SWOT Analysis of global and regional Primary Ciliary Dyskinesia markets

- Competitive analysis including business description, product analysis, and financial profiles

Key country specific analysis detailing key factors shaping the short-term and long-term outlook

Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Primary Ciliary Dyskinesia Market Competitive Benchmarking and Company Analysis

Leading companies in Primary Ciliary Dyskinesia industry include- Parion Sciences, ReCode Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Reata Pharmaceuticals, Ethris GmbH, Vertex Pharmaceuticals, Nobelpharma Co., Ltd., Bayer AG, GlaxoSmithKline plc. The Primary Ciliary Dyskinesia market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Primary Ciliary Dyskinesia Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach \$8.2 Trillion in 2034 from \$5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Primary Ciliary Dyskinesia market remains one of the strongest-performing segments in the country.

The US Primary Ciliary Dyskinesia Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Primary Ciliary Dyskinesia market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across

Primary Ciliary Dyskinesia industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Primary Ciliary Dyskinesia markets

Canada's strong Primary Ciliary Dyskinesia sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Primary Ciliary Dyskinesia market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada's largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Primary Ciliary Dyskinesia Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Primary Ciliary Dyskinesia market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Primary Ciliary Dyskinesia population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Primary Ciliary Dyskinesia industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Primary Ciliary Dyskinesia market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Primary Ciliary Dyskinesia sales through 2034

France Primary Ciliary Dyskinesia companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country's

National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country's healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.

The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France's market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Primary Ciliary Dyskinesia Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Primary Ciliary Dyskinesia distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England's plan to give more than 500,000 staff access to new AI tools.

China Primary Ciliary Dyskinesia Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Primary Ciliary Dyskinesia market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Primary Ciliary Dyskinesia industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.

The National Healthcare Security Administration reported that by end-2024, China's basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Primary Ciliary Dyskinesia industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Primary Ciliary Dyskinesia Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Primary Ciliary Dyskinesia market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Primary Ciliary Dyskinesia market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Primary Ciliary Dyskinesia Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending.

Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Primary Ciliary Dyskinesia Market Segmentation

By Treatment

Pharmacological Therapy

Gene Therapy

Supportive Care

By Diagnostic Tool

Genetic Testing

Nasal Nitric Oxide Measurement

High-Speed Video Microscopy

By Disease Manifestation

Pulmonary Disease

Situs Abnormality

Infertility

Eye disorders

By Patient Age Group

0-5 Years

6-20 Years

21-40 Years

40+ Years

Leading Companies in Primary Ciliary Dyskinesia Industry (2026)

Parion Sciences

ReCode Therapeutics

Vertex Pharmaceuticals

Arrowhead Pharmaceuticals

Reata Pharmaceuticals

Ethris GmbH

Vertex Pharmaceuticals

Nobelpharma Co., Ltd.

Bayer AG

GlaxoSmithKline plc

Countries Included

North America- US, Canada, Mexico

Europe- Germany, France, UK, Spain, Italy, Nordics, Others

Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia,
Others

Latin America- Brazil, Argentina, Others

Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa,

Other Africa

Key Benefits of Procuring the Analysis

Get Free print authentication across single, multi, and global licenses

Free Accompanying excel spreadsheet with complete quantitative data

Free 2-day consulting support from the lead analyst of the team that developed the report

Strategic Value of the Electrosurgical Generators Market Analysis

Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly

Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry

Stay ahead of competition through a detailed analysis of recent market developments

Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry

Contents

CHAPTER 1- EXECUTIVE SUMMARY

- 1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
- 1.2. Key Industry Highlights, 2026
- 1.3. Premium Market Insights
 - 1.3.1. Potential Primary Ciliary Dyskinesia Market Types and Applications
 - 1.3.2. Fastest Growing Countries Over the forecast period
- 1.4. Market Scope and Segmentation
 - 1.4.1. Key Market Segments
 - 1.4.2. Key Countries and Regions
 - 1.4.3. Top Companies in the Primary Ciliary Dyskinesia Industry
- 1.5. Macroeconomic and Demographic Outlook
 - 1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
 - 1.5.2. Population Forecast by Country, 2010- 2040
 - 1.5.3. Inflation Trends in Leading Countries
- 1.6. Impact of Trade Policies, Regulations, and Sustainability
 - 1.6.1. Trade tariffs and localization requirements
 - 1.6.2. ESG and sustainability pressures
 - 1.6.3. Compliance-driven structural changes in the value chain

CHAPTER 2- RESEARCH METHODOLOGY

- 2.1. Report Coverage
- 2.2. Secondary Research
- 2.3. Primary Research
- 2.4. Data Triangulation
- 2.5. Market Modeling and Forecasting

CHAPTER 3- GLOBAL PRIMARY CILIARY DYSKINESIA MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034

- 3.1. An Introduction to Global Primary Ciliary Dyskinesia Markets in 2026
- 3.2. Global Historic and Forecast Primary Ciliary Dyskinesia Market Size Outlook, USD Million, 2021- 2034
- 3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
- 3.4. Market Dynamics
 - 3.4.1. Key Primary Ciliary Dyskinesia Market Driving Forces and Their Impact on

Market Outlook

3.4.2. Short and Long-Term Trends and Insights Shaping the Future

3.4.3. Potential Primary Ciliary Dyskinesia Market Opportunities for Industry

Stakeholders

3.4.4. Potential Challenges across Primary Ciliary Dyskinesia Value Chain

CHAPTER 4- PRIMARY CILIARY DYSKINESIA MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT

4.1. Porter's Five Forces Analysis

4.1.1. Bargaining Power of Buyers

4.1.2. Bargaining Power of Suppliers

4.1.3. Threat of Substitutes

4.1.4. Threat of New Entrants

4.1.5. Intensity of Competitive Rivalry

4.1.6. Market Attractiveness Analysis by Segment

4.1.7. Market Attractiveness Analysis by Region

4.2. Competitive Landscape

4.2.1 Market Share Analysis of Leading Primary Ciliary Dyskinesia Companies

4.2.2 Recent Strategic Developments

4.2.3 Mergers, Acquisitions, and Partnerships

4.2.4 Product Launches and Innovation Trends

4.2.5 Key Success Factors

4.3. Value Chain Analysis

4.3.1. Key Value Chain Segments

4.3.2. Dominant players by value-chain stage

4.4. SWOT Analysis

4.4.1. Key Strengths and Opportunities

4.4.2. Major Weaknesses and Threats

4.5 Technology Roadmap

4.6 Regulatory and Reimbursement Landscape

CHAPTER 5- PRIMARY CILIARY DYSKINESIA MARKET OUTLOOK BY SEGMENTS

5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034

5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034

5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034

By Treatment

Pharmacological Therapy

Gene Therapy
Supportive Care
By Diagnostic Tool
Genetic Testing
Nasal Nitric Oxide Measurement
High-Speed Video Microscopy
By Disease Manifestation
Pulmonary Disease
Situs Abnormality
Infertility
Eye disorders
By Patient Age Group
0-5 YEARS
6-20 YEARS
21-40 YEARS
40+ YEARS

CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK

- 6.1. Base Case Scenario
 - 6.1.1. Definitions and Insights
 - 6.1.2. Market Size Outlook to 2034
- 6.2. Low Growth Case Scenario
 - 6.2.1. Definitions and Insights
 - 6.2.2. Market Size Outlook to 2034
- 6.3. High Growth Case Scenario
 - 6.3.1. Definitions and Insights
 - 6.3.2. Market Size Outlook to 2034

CHAPTER 7- NORTH AMERICA PRIMARY CILIARY DYSKINESIA MARKET SIZE ANALYSIS AND OUTLOOK

- 7.1. North America Primary Ciliary Dyskinesia Market Overview, 2026
- 7.2. Leading Companies Operating in North America
- 7.3. Key Industry Statistics, 2026
- 7.4. North America Primary Ciliary Dyskinesia Market Trends and Growth Opportunities to 2034
- 7.5. North America Primary Ciliary Dyskinesia Market Size Outlook by Type
- 7.6. North America Primary Ciliary Dyskinesia Market Size Outlook by Application

7.7. North America Primary Ciliary Dyskinesia Market Size Outlook by Country

7.8. United States

7.8.1. Key Statistics

7.8.2. The US Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034

7.8.3. Key Market Drivers and Industry Developments in the US Primary Ciliary Dyskinesia Companies

7.9. Canada

7.9.1. Key Statistics

7.9.2. Canada Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034

7.9.3. Key Market Drivers and Industry Developments in Canada Primary Ciliary Dyskinesia Companies

7.10. Mexico

7.10.1. Key Statistics

7.10.2. Mexico Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034

7.10.3. Key Market Drivers and Industry Developments in Mexico Primary Ciliary Dyskinesia Companies

CHAPTER 8- EUROPE PRIMARY CILIARY DYSKINESIA MARKET SIZE ANALYSIS AND OUTLOOK

8.1. Europe Primary Ciliary Dyskinesia Market Overview, 2026

8.2. Leading Companies Operating in Europe

8.3. Key Industry Statistics, 2026

8.4. Europe Primary Ciliary Dyskinesia Market Trends and Growth Opportunities to 2034

8.5. Europe Primary Ciliary Dyskinesia Market Size Outlook by Type

8.6. Europe Primary Ciliary Dyskinesia Market Size Outlook by Application

8.7. Europe Primary Ciliary Dyskinesia Market Size Outlook by Country

8.8. Germany

8.8.1. Key Statistics

8.8.2. Germany Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034

8.8.3. Key Market Drivers and Industry Developments in Germany Primary Ciliary Dyskinesia Companies

8.9. France

8.9.1. Key Statistics

8.9.2. France Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034

8.9.3. Key Market Drivers and Industry Developments in France Primary Ciliary Dyskinesia Companies

8.10. United Kingdom

- 8.10.1. Key Statistics
- 8.10.2. United Kingdom Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034
- 8.10.3. Key Market Drivers and Industry Developments in the UK Primary Ciliary Dyskinesia Companies
- 8.11. Spain
 - 8.11.1. Key Statistics
 - 8.11.2. Spain Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034
 - 8.11.3. Key Market Drivers and Industry Developments in Spain Primary Ciliary Dyskinesia Companies
- 8.12. Italy
 - 8.12.1. Key Statistics
 - 8.12.2. Italy Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034
 - 8.12.3. Key Market Drivers and Industry Developments in Italy Primary Ciliary Dyskinesia Companies
- 8.13. Rest of Europe
 - 8.13.1. Key Statistics
 - 8.13.2. Rest of Europe Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034
 - 8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Primary Ciliary Dyskinesia Companies

CHAPTER 9- ASIA PACIFIC PRIMARY CILIARY DYSKINESIA MARKET SIZE ANALYSIS AND OUTLOOK

- 9.1. Asia Pacific Primary Ciliary Dyskinesia Market Overview, 2026
- 9.2. Leading Companies Operating in Asia Pacific
- 9.3. Key Industry Statistics, 2026
- 9.4. Asia Pacific Primary Ciliary Dyskinesia Market Trends and Growth Opportunities to 2034
- 9.5. Asia Pacific Primary Ciliary Dyskinesia Market Size Outlook by Type
- 9.6. Asia Pacific Primary Ciliary Dyskinesia Market Size Outlook by Application
- 9.7. Asia Pacific Primary Ciliary Dyskinesia Market Size Outlook by Country
- 9.8. China
 - 9.8.1. Key Statistics
 - 9.8.2. China Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034
 - 9.8.3. Key Market Drivers and Industry Developments in China Primary Ciliary Dyskinesia Companies
- 9.9. Japan
 - 9.9.1. Key Statistics
 - 9.9.2. Japan Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034

9.9.3. Key Market Drivers and Industry Developments in Japan Primary Ciliary Dyskinesia Companies

9.10. India

9.10.1. Key Statistics

9.10.2. India Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034

9.10.3. Key Market Drivers and Industry Developments in India Primary Ciliary Dyskinesia Companies

9.11. South Korea

9.11.1. Key Statistics

9.11.2. South Korea Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034

9.11.3. Key Market Drivers and Industry Developments in South Korea Primary Ciliary Dyskinesia Companies

9.12. Australia

9.12.1. Key Statistics

9.12.2. Australia Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034

9.12.3. Key Market Drivers and Industry Developments in Australia Primary Ciliary Dyskinesia Companies

9.13. Southeast Asia

9.13.1. Key Statistics

9.13.2. Southeast Asia Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034

9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Primary Ciliary Dyskinesia Companies

CHAPTER 10- SOUTH AND CENTRAL AMERICA PRIMARY CILIARY DYSKINESIA MARKET SIZE ANALYSIS AND OUTLOOK

10.1. South and Central America Primary Ciliary Dyskinesia Market Overview, 2026

10.2. Leading Companies Operating in South and Central America

10.3. Key Industry Statistics, 2026

10.4. South and Central America Primary Ciliary Dyskinesia Market Trends and Growth Opportunities to 2034

10.5. South and Central America Primary Ciliary Dyskinesia Market Size Outlook by Type

10.6. South and Central America Primary Ciliary Dyskinesia Market Size Outlook by Application

10.7. South and Central America Primary Ciliary Dyskinesia Market Size Outlook by Country

10.8. Brazil

10.8.1. Key Statistics

- 10.8.2. Brazil Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034
- 10.8.3. Key Market Drivers and Industry Developments in Brazil Primary Ciliary Dyskinesia Companies
- 10.9. Argentina
 - 10.9.1. Key Statistics
 - 10.9.2. Argentina Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034
 - 10.9.3. Key Market Drivers and Industry Developments in Argentina Primary Ciliary Dyskinesia Companies
- 10.10. Rest of Latin America
 - 10.10.1. Key Statistics
 - 10.10.2. Rest of Latin America Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034
 - 10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Primary Ciliary Dyskinesia Companies

CHAPTER 11- MIDDLE EAST AND AFRICA PRIMARY CILIARY DYSKINESIA MARKET SIZE ANALYSIS AND OUTLOOK

- 11.1. Middle East and Africa Primary Ciliary Dyskinesia Market Overview, 2026
- 11.2. Leading Companies Operating in Middle East and Africa
- 11.3. Key Industry Statistics, 2026
- 11.4. Middle East and Africa Primary Ciliary Dyskinesia Market Trends and Growth Opportunities to 2034
- 11.5. Middle East and Africa Primary Ciliary Dyskinesia Market Size Outlook by Type
- 11.6. Middle East and Africa Primary Ciliary Dyskinesia Market Size Outlook by Application
- 11.7. Middle East and Africa Primary Ciliary Dyskinesia Market Size Outlook by Country
- 11.8. Saudi Arabia
 - 11.8.1. Key Statistics
 - 11.8.2. Saudi Arabia Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034
 - 11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Primary Ciliary Dyskinesia Companies
- 11.9. United Arab Emirates
 - 11.9.1. Key Statistics
 - 11.9.2. The UAE Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034
 - 11.9.3. Key Market Drivers and Industry Developments in the UAE Primary Ciliary Dyskinesia Companies
- 11.10. Africa
 - 11.10.1. Key Statistics

11.10.2. Africa Primary Ciliary Dyskinesia Market Size Outlook, 2021- 2034

11.10.3. Key Market Drivers and Industry Developments in Africa Primary Ciliary Dyskinesia Companies

CHAPTER 12- COMPANY PROFILES

12.1. Top Companies in Primary Ciliary Dyskinesia Industry

Parion Sciences

ReCode Therapeutics

Vertex Pharmaceuticals

Arrowhead Pharmaceuticals

Reata Pharmaceuticals

Ethris GmbH

Vertex Pharmaceuticals

Nobelpharma Co., Ltd.

Bayer AG

GlaxoSmithKline plc

12.2. Business Description

12.3. SWOT Profiles

12.4. Products and Services

CHAPTER 13- APPENDIX

Glossary of Terms

Research Methodology & Data Sources

Conclusion & Strategic Recommendations

I would like to order

Product name: Primary Ciliary Dyskinesia Market Size, Share and Growth Outlook 2026: By Treatment (Pharmacological Therapy, Gene Therapy, Supportive Care), By Diagnostic Tool, By Disease Manifestation, By Patient Age Group, Companies to 2034.

Product link: <https://marketpublishers.com/r/P6E60F63108AEN.html>

Price: US\$ 3,482.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P6E60F63108AEN.html>